Akèy › Twoub depresif majè › Connecticut
Etid klinik pou Twoub depresif majè nan Connecticut
16 etid pou Twoub depresif majè ap chèche patisipan nan sit nan Connecticut.
Vil nan Connecticut
Tèks ofisyèl etid la (Anglè)
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- UConn Health Center, Farmington
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Connecticut Health Center, Farmington
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT05850689A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
Ap rekriteFaz 3
Laj 18 a 85 · Tout sèks · Mizajou Sep 25, 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Institute of Living, Hartford
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 8, 2026 · NCT07076407A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 6, 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Ct Clinical Research Associates, Cromwell
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Aug 3, 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Connecticut School of Medicine Psychiatry Department, Farmington
Ap rekriteFaz 2
Laj 18 a 64 · Tout sèks · Mizajou Aug 3, 2026 · NCT06547489A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New Haven
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT06966401The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
Ap rekriteFaz 2
Laj 21 a 65 · Tout sèks · Mizajou May 6, 2026 · NCT05786066Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Yale University, New Haven
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou May 6, 2026 · NCT05915013Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Hartford Hospital, Hartford
Ap rekriteEtid obsèvasyon
Laj 18 a 40 · Tout sèks · Mizajou Mar 10, 2026 · NCT06740383Imaging Depression in Parkinson's Disease
- Yale University, New Haven
Ap rekriteFaz 2Volontè an sante akeyi
Laj 40 a 80 · Tout sèks · Mizajou Mar 10, 2026 · NCT06402955Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #122, Cromwell
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Jan 20, 2026 · NCT06633016Study of ALTO-300 in MDD
- Site 214, Norwalk
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 24, 2025 · NCT05922878Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.